Table 3Pooled relative risks of major outcomes for the comparison of each newer antiplatelet agent with aspirin alone following stroke or transient ischemic attack

Newer antiplatelet agentAll-cause mortalityCardiovascular mortalityStroke
Fixed-dose combination of extended-release dipyridamole plus aspirinRR, 0.96 (0.83 to 1.13)RR, 0.74 (0.51 to 1.08)RR, 0.84 (0.73 to 0.98)
ClopidogrelNot reportedRR, 0.99 (0.75 to 1.29)RR, 0.92 (0.79 to 1.07)
TiclopidineRR, 0.94 (0.79 to 1.12)RR, 1.16 (0.89 to 1.52)RR, 0.94 (0.81 to 1.10)

Abbreviations: RR, relative risk.

From: Results

Cover of Drug Class Review: Newer Antiplatelet Agents
Drug Class Review: Newer Antiplatelet Agents: Final Update 2 Report [Internet].
Ketchum K, Peterson K, Thakurta S, et al.
Portland (OR): Oregon Health & Science University; 2011 Jun.
Copyright © 2011 by Oregon Health & Science University.

NCBI Bookshelf. A service of the National Library of Medicine, National Institutes of Health.